Prinses Maxima Centrum voor Kinderoncologie B.V. — Clinical Trial Site

93 Registered trials

55 Currently recruiting

Organisation

Prinses Maxima Centrum voor Kinderoncologie B.V.

Location

Utrecht, Netherlands

Identifier

ORG-100011005

Address

Heidelberglaan 25, 3584 CS, Netherlands

Departments

-
#1101:Kinderoncologie
#9100; Trial and data center
2100:Trial and data center
2200: Pediatric Oncology
3401:Pediatric oncology
528003: Pediatric Oncology
Afdeling hematologie
Department of Hemato-oncology
Department of Paediatrics
Department pediatric Hemato-Oncology
Department Solid Tumours
Haemato-oncology
Hemato-oncology
Hematology
Hematology-oncology
Hematooncology
HO
Kinderoncologie
N/A
Neuro-oncologie
Neuro-oncology
Neurooncology
NO
Oncology
Paediatric Oncology
Ped Oncology
Pediatric Hem/Onc
Pediatric hemato-Oncology
Pediatric Hematology/Oncology Department
Pediatric Oncologist
Pediatric Oncology
Pediatrics
Princess Maxima Center for Pediatric Oncology
Prinses Maxima Centrum voor Kinderoncologie
SO
Solid Tumor Department
Solid Tumors
Solid Tumours
Specialisten SO
Specialists HO
Stem cell Transplantation and cellular therapy
Supportive Care
Surgery
TDC
Trial and data center
Trial en Data Center
Utrecht Afdeling solide tumoren

Clinical trials at this site (93)

Search interface

The PACMAN-Hu19 trial: a phase I/II study with locally produced CD19-targeted CAR T-cell therapy Pending

2023-507597-40-00 B-cell precursor ALL 9
IntReALL BCP 2020 – International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 Pending

2023-509392-17-00 Relapsed Acute Lymphoblastic Leukemia (ALL) 5
PNOC029_Tovorafenib for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults Pending

2024-511510-20-00 craniopharyngioma 4
SIOP PNET 5 medulloblastoma Pending

2024-513724-42-00 Medulloblastoma 10
Comparison of neurocognitive outcome in two standard regimen for treatment of low-risk medulloblastoma (COGNITO-MB) Pending

2024-517133-40-00 newly diagnosed, non-metastatic, SHH-activated, TP53-wt 5
FIDES: Focused Ultrasound-mediated Blood-Brain Barrier Opening In Pontine Diffuse Midline Glioma (DMG) to Enhance Systemic Therapy with Temo… Pending

2025-520814-78-00 Diffuse Midline Glioma, H3K27-altered 9
A phase 1/2 study of subcutaneous blinatumomab administration in children with R/R and MRD+ B-ALL Pending

2025-521671-31-00 Relapsed/Refractory (R/R) and Minimal Residual Disease 9
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL Pending

2025-522019-40-00 relapsed or refractory BCR::ABL1-positive (Philadelphia 9
A medical research to evaluate if MaaT013 is safe and helps children and adolescent with GI-aGvHD after failed two prior therapies. Pending

2025-524302-15-00 Gastrointestinal Acute Graft-versus-Host Disease (GI-aG 4
THRILL: Treat Hyperinflammation in child oncology study Pending

2025-524541-27-00 Sepsis 4
A clinical trial of MK-1045 in people with B-cell acute lymphoblastic leukemia Recruiting

2025-522267-15-00 Relapsed/refractory B-cell Acute Lymphoblastic Leukemi 10 2026-06-24
Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukem… Recruiting

2025-521390-14-00 Acute Myeloid Leukemia 4 2026-06-22
INTRATUMORAL DNX-2401 ADMINISTRATION FOR RECURRENT AND REFRACTORY HIGH GRADE BRAIN TUMORS IN PEDIATRIC AND YOUNG ADULT PATIENTS Recruiting

2024-515009-24-00 High grade malignant brain neoplasm 4 2026-05-08
A study of belumosudil in children with chronic graft versus host disease (schoolROCK). Recruiting

2024-511508-18-00 Chronic graft versus host disease. 9 2026-01-05
Clinical study of ruxolitinib and venetoclax for children with relapsed or refractory leukemia or lymphoma with mutations in the IL-7R/JAK-S… Recruiting

2022-501867-42-01 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic 9 2025-09-08
Medical-scientific study of dasatinib and venetoclax for children with relapsed or refractory leukemia or lymphoma with a mutation in the MA… Recruiting

2022-501866-22-00 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic 9 2025-08-26
A study to determine how safe MB-CART2019.1 is and how well it works in children and adolescents with B cell neoplasms Recruiting

2023-506348-17-00 Relapsed/refractory (r/r) mature B cell neoplasms who h 4 2025-07-22
Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimeta… Recruiting

2023-503322-39-00 Newly diagnosed patients with metastatic (other than lu 3 2023-06-16
A Ph2 Superiority Study with InO Monotherapy vs ALLR3 for Induction Treatment of Childhood HR ALL Recruiting

2023-509810-13-00 Acute Lymphoblastic Leukemia (ALL) 4 2023-05-13
Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting

2022-502503-30-00 Acute lymphoblastic leukemia 5 2022-12-15
Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia Recruiting

2023-504694-20-00 pediatric CD22-positive relapsed/refractory Acute Lymph 9 2017-01-13
Study to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia. Recruiting

2025-522138-29-00 Philadelphia positive Chronic Myeloid leukemia in Chron 4 2026-06-18
Indocyanine Green and near infrared fLuorescence in paediatric Oncology surgery Recruiting

2024-514089-37-00 Patients with pulmonary metastasis from any primary tum 4 2026-06-16
The INFLUENCE Trial: Improve CAR T cell therapy by optimizing fludarabine exposure Recruiting

2025-523096-34-00 B-cell Acute Lymphoblastic Leukemia 5 2026-06-11